{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:36:19Z","timestamp":1782423379206,"version":"3.54.5"},"reference-count":47,"publisher":"e-Century Publishing Corporation","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/idkg8587","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:46:18Z","timestamp":1720046778000},"page":"3068-3082","source":"Crossref","is-referenced-by-count":4,"title":["The inhibitory and transcriptional effects of the epigenetic repurposed drugs hydralazine and valproate in lymphoma cells"],"prefix":"10.62347","volume":"14","author":[{"given":"Harold","family":"Salamanca-Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2217\/epi.13.39","article-title":"Combating the epigenome: epigenetic drugs against non-Hodgkin’s lymphoma","volume":"5","author":"MR","year":"2013","unstructured":"Hassler MR, Schiefer AI and Egger G. Combating the epigenome: epigenetic drugs against non-Hodgkin’s lymphoma. Epigenomics 2013; 5: 397-415.","journal-title":"Epigenomics"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Lue JK, Amengual JE and O’Connor OA. Epigenetics and lymphoma: can we use epigenetics to prime or reset chemoresistant lymphoma programs? Curr Oncol Rep 2015; 17: 40.","DOI":"10.1007\/s11912-015-0464-y"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","article-title":"Emerging epigenetic-modulating therapies in lymphoma","volume":"16","author":"Sermer","year":"2019","unstructured":"Sermer D, Pasqualucci L, Wendel HG, Melnick A and Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol 2019; 16: 494-507.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2407-5-44","article-title":"A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes","volume":"5","author":"Zambrano","year":"2005","unstructured":"Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L, Chavez-Blanco A, Angeles E, Cabrera G, Sandoval K, Trejo-Becerril C, Chanona-Vilchis J and Duenas-Gonzalez A. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005; 5: 44.","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-4598-4-22","article-title":"A phase I study","volume":"4","author":"Chavez-Blanco","year":"2005","unstructured":"Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M, Cantu D, Gonzalez-Fierro A, Garcia-Lopez P, Zambrano P, Perez-Plasencia C, Cabrera G, Trejo-Becerril C, Angeles E and Duenas-Gonzalez A. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 2005; 4: 22.","journal-title":"Mol Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.tranon.2014.03.001","article-title":"A phase I protocol of hydralazine and valproic acid in advanced, previously treated solid cancers","volume":"7","author":"Bauman","year":"2014","unstructured":"Bauman J, Shaheen M, Verschraegen CF, Belinsky SA, Houman Fekrazad M, Lee FC, Rabinowitz I, Ravindranathan M and Jones DV Jr. A phase I protocol of hydralazine and valproic acid in advanced, previously treated solid cancers. Transl Oncol 2014; 7: 349-354.","journal-title":"Transl Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00277-010-1090-2","article-title":"Preliminary results of a phase-II trial","volume":"90","author":"Candelaria","year":"2011","unstructured":"Candelaria M, Herrera A, Labardini J, Gonzalez-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Perez-Cardenas E, de la Cruz-Hernandez E, Arias-Bofill D, Vidal S, Cervera E and Duenas-Gonzalez A. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol 2011; 90: 379-387.","journal-title":"Ann Hematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00277-017-3103-x","article-title":"Encouraging results with the compassionate use of hydralazine\/valproate (TRANSKRIP) as epigenetic treatment for myelodysplastic syndrome (MDS)","volume":"96","author":"Candelaria","year":"2017","unstructured":"Candelaria M, Burgos S, Ponce M, Espinoza R and Duenas-Gonzalez A. Encouraging results with the compassionate use of hydralazine\/valproate (TRANSKRIP) as epigenetic treatment for myelodysplastic syndrome (MDS). Ann Hematol 2017; 96: 1825-1832.","journal-title":"Ann Hematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/13543784.2017.1291630","article-title":"Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study","volume":"26","author":"Espinoza-Zamora","year":"2017","unstructured":"Espinoza-Zamora JR, Labardini-Mendez J, Sosa-Espinoza A, Lopez-Gonzalez C, Vieyra-Garcia M, Candelaria M, Lozano-Zavaleta V, Toledano-Cuevas DV, Zapata-Canto N, Cervera E and Duenas-Gonzalez A. Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study. Expert Opin Investig Drugs 2017; 26: 481-487.","journal-title":"Expert Opin Investig Drugs"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.clml.2012.11.009","article-title":"Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study","volume":"13","author":"Malik","year":"2013","unstructured":"Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ and Estrov Z. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymphoma Myeloma Leuk 2013; 13: 292-295.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.2010.08213.x","article-title":"Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation","volume":"150","author":"Blum","year":"2010","unstructured":"Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR and Byrd JC. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol 2010; 150: 189-195.","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"371087","DOI":"10.1155\/2014\/371087","article-title":"Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I\/II report","volume":"2014","author":"Fan","year":"2014","unstructured":"Fan H, Lu X, Wang X, Liu Y, Guo B, Zhang Y, Zhang W, Nie J, Feng K, Chen M, Zhang Y, Wang Y, Shi F, Fu X, Zhu H and Han W. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I\/II report. J Immunol Res 2014; 2014: 371087.","journal-title":"J Immunol Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","article-title":"Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma","volume":"3","author":"Clozel","year":"2013","unstructured":"Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden KL, Inghirami G, Leonard JP, Melnick A and Cerchietti L. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 2013; 3: 1002-1019.","journal-title":"Cancer Discov"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2021011679","article-title":"Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL","volume":"139","author":"Martin","year":"2022","unstructured":"Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones J, Drew J, Wu C, Mulvey E, Revuelta MV, Cerchietti L and Leonard JP. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood 2022; 139: 1147-1159.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","unstructured":"Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, Terauchi T, Yamamoto K, Mori M, Tanaka Y, Shimamoto T, Tobinai K and Kim WS. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol 2014; 165: 768-776.","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","unstructured":"Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D and Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 1198-1203.","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","author":"Chen","year":"2015","unstructured":"Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, Htut M, Nademanee A, Forman SJ and Kirschbaum M. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma. Haematologica 2015; 100: 357-362.","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Tan D, Phipps C, Hwang WY, Tan SY, Yeap CH, Chan YH, Tay K, Lim ST, Lee YS, Kumar SG, Ng SC, Fadilah S, Kim WS and Goh YT; SGH651 Investigators. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol 2015; 2: e326-333.","DOI":"10.1016\/S2352-3026(15)00097-6"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/ajh.25010","article-title":"A phase I\/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806","volume":"93","author":"Persky","year":"2018","unstructured":"Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, Von Gehr A, LeBlanc M, Fisher RI, Smith SM and Friedberg JW. A phase I\/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 2018; 93: 486-493.","journal-title":"Am J Hematol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bjh.12230","article-title":"A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma","volume":"161","author":"Budde","year":"2013","unstructured":"Budde LE, Zhang MM, Shustov AR, Pagel JM, Gooley TA, Oliveira GR, Chen TL, Knudsen NL, Roden JE, Kammerer BE, Frayo SL, Warr TA, Boyd TE, Press OW and Gopal AK. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. Br J Haematol 2013; 161: 183-191.","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/10428194.2017.1359741","article-title":"Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma","volume":"59","author":"Hu","year":"2018","unstructured":"Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA and Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 2018; 59: 863-870.","journal-title":"Leuk Lymphoma"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1182\/bloodadvances.2018019240","article-title":"Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)","volume":"2","author":"Drott","year":"2018","unstructured":"Drott K, Hagberg H, Papworth K, Relander T and Jerkeman M. Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID). Blood Adv 2018; 2: 1386-1392.","journal-title":"Blood Adv"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Gore SD. In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res 2009; 33 Suppl 2: S2-6.","DOI":"10.1016\/S0145-2126(09)70226-7"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Hellebrekers DM, Griffioen AW and van Engeland M. Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta 2007; 1775: 76-91.","DOI":"10.1016\/j.bbcan.2006.07.003"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Xu QY and Yu L. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors. Chin Med J (Engl) 2020; 133: 699-715.","DOI":"10.1097\/CM9.0000000000000685"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13148-016-0245-y","article-title":"Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients","volume":"8","author":"Pera","year":"2016","unstructured":"Pera B, Tang T, Marullo R, Yang SN, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J, Cerchietti L and Martin P. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clin Epigenetics 2016; 8: 79.","journal-title":"Clin Epigenetics"},{"key":"ref26","unstructured":"Schcolnik-Cabrera A, Dominguez-Gomez G and Duenas-Gonzalez A. Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous T-cell lymphoma in HUT78 cells. Am J Blood Res 2018; 8: 5-16."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","article-title":"HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL","volume":"118","author":"Kalac","year":"2011","unstructured":"Kalac M, Scotto L, Marchi E, Amengual J, Seshan VE, Bhagat G, Ulahannan N, Leshchenko VV, Temkin AM, Parekh S, Tycko B and O’Connor OA. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 2011; 118: 5506-5516.","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/cncr.30100","article-title":"Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma","volume":"122","author":"Nieto","year":"2016","unstructured":"Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R and Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer 2016; 122: 2680-2688.","journal-title":"Cancer"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Amengual JE. Can we use epigenetics to prime chemoresistant lymphomas? Hematology Am Soc Hematol Educ Program 2020; 2020: 85-94.","DOI":"10.1182\/hematology.2020000092"},{"key":"ref30","unstructured":"Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ and Siu LL. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Clin Cancer Res 2009; 27: 3528."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","article-title":"The rise of apoptosis: targeting apoptosis in hematologic malignancies","volume":"132","author":"Valentin","year":"2018","unstructured":"Valentin R, Grabow S and Davids MS. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood 2018; 132: 1248-1264.","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3390\/cancers12040938","article-title":"BCL-2 proteins in pathogenesis and therapy of B-cell non-hodgkin lymphomas","volume":"12","author":"Klanova","year":"2020","unstructured":"Klanova M and Klener P. BCL-2 proteins in pathogenesis and therapy of B-cell non-hodgkin lymphomas. Cancers (Basel) 2020; 12: 938.","journal-title":"Cancers (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Deng J. How to unleash mitochondrial apoptotic blockades to kill cancers? Acta Pharm Sin B 2017; 7: 18-26.","DOI":"10.1016\/j.apsb.2016.08.005"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/sj.cgt.7700792","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in cancer","volume":"12","author":"Zhang","year":"2005","unstructured":"Zhang L and Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228-237.","journal-title":"Cancer Gene Ther"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1182\/blood-2014-01-553412","article-title":"FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-kappaB to promote survival of human B cells","volume":"124","author":"van Keimpema","year":"2014","unstructured":"van Keimpema M, Gruneberg LJ, Mokry M, van Boxtel R, Koster J, Coffer PJ, Pals ST and Spaargaren M. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-kappaB to promote survival of human B cells. Blood 2014; 124: 3431-3440.","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1081\/DMR-120026497","article-title":"Chemical-induced apoptosis: formation of the Apaf-1 apoptosome","volume":"35","author":"Cain","year":"2003","unstructured":"Cain K. Chemical-induced apoptosis: formation of the Apaf-1 apoptosome. Drug Metab Rev 2003; 35: 337-363.","journal-title":"Drug Metab Rev"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.febslet.2004.05.057","article-title":"A P53 target gene, PIG11, contributes to chemosensitivity of cells to arsenic trioxide","volume":"569","author":"Liang","year":"2004","unstructured":"Liang XQ, Cao EH, Zhang Y and Qin JF. A P53 target gene, PIG11, contributes to chemosensitivity of cells to arsenic trioxide. FEBS Lett 2004; 569: 94-98.","journal-title":"FEBS Lett"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","unstructured":"Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN, Xiao Y, Solomon LR, Boghaert ER, Leverson JD and Phillips DC. 5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res 2020; 26: 3371-3383.","journal-title":"Clin Cancer Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1038\/onc.2008.301","article-title":"JNK signaling in apoptosis","volume":"27","author":"Dhanasekaran","year":"2008","unstructured":"Dhanasekaran DN and Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27: 6245-6251.","journal-title":"Oncogene"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3892\/ol.2020.12318","article-title":"Soluble CD40 ligand inhibits the growth of non-Hodgkin’s lymphoma cells through the JNK signaling pathway","volume":"21","author":"Feng","year":"2021","unstructured":"Feng Z and Wang J. Soluble CD40 ligand inhibits the growth of non-Hodgkin’s lymphoma cells through the JNK signaling pathway. Oncol Lett 2021; 21: 56.","journal-title":"Oncol Lett"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"113036","DOI":"10.1016\/j.ejmech.2020.113036","article-title":"Synthesis and in vitro evaluation of novel spiroketopyrazoles as acetyl-CoA carboxylase inhibitors and potential antitumor agents","volume":"212","author":"Huang","year":"2021","unstructured":"Huang T, Wu X, Yan S, Liu T and Yin X. Synthesis and in vitro evaluation of novel spiroketopyrazoles as acetyl-CoA carboxylase inhibitors and potential antitumor agents. Eur J Med Chem 2021; 212: 113036.","journal-title":"Eur J Med Chem"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"103071","DOI":"10.1016\/j.critrevonc.2020.103071","article-title":"Function and regulation of lipid signaling in lymphomagenesis: a novel target in cancer research and therapy","volume":"154","author":"Guo","year":"2020","unstructured":"Guo W, Wang X, Li Y and Bai O. Function and regulation of lipid signaling in lymphomagenesis: a novel target in cancer research and therapy. Crit Rev Oncol Hematol 2020; 154: 103071.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.bbagen.2013.09.020","article-title":"Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype","volume":"1840","author":"Kant","year":"2014","unstructured":"Kant S, Kumar A and Singh SM. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochim Biophys Acta 2014; 1840: 294-302.","journal-title":"Biochim Biophys Acta"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.4049\/jimmunol.1800137","article-title":"Disrupting the code: epigenetic dysregulation of lymphocyte function during infectious disease and lymphoma development","volume":"201","author":"Di Pietro","year":"2018","unstructured":"Di Pietro A and Good-Jacobson KL. Disrupting the code: epigenetic dysregulation of lymphocyte function during infectious disease and lymphoma development. J Immunol 2018; 201: 1109-1118.","journal-title":"J Immunol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","article-title":"Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses","volume":"10","author":"Chen","year":"2020","unstructured":"Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, Yang B and Ding L. Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B 2020; 10: 723-733.","journal-title":"Acta Pharm Sin B"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/jcpt.12155","article-title":"Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine\/valproate exposure","volume":"39","author":"Garces-Eisele","year":"2014","unstructured":"Garces-Eisele SJ, Cedillo-Carvallo B, Reyes-Nunez V, Estrada-Marin L, Vazquez-Perez R, Juarez-Calderon M, Guzman-Garcia MO, Duenas-Gonzalez A and Ruiz-Arguelles A. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine\/valproate exposure. J Clin Pharm Ther 2014; 39: 368-375.","journal-title":"J Clin Pharm Ther"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/6\/ajcr0156241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:54:00Z","timestamp":1766022840000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/6\/ajcr0156241.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/idkg8587","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}